Sentence examples for pharmacodynamic potency from inspiring English sources

The objective of this study was to develop quantitative models to delineate the net efficacy of taspoglutide on fasting plasma glucose (FPG) and glycosylated hemoglobin (HbA1c) from the response of placebo in type 2 diabetes patients, and further find pharmacodynamic potency of taspoglutide and FPG for half of maximum reduction responses of FPG and HbA1c, respectively.

The pharmacodynamic potency (25.3 pmol/l) produced 50% of maximum responses of FPG (−2.39 mmol/l) from the responses of placebo for FPG (−0.371 mmol/l); the response change of FPG (−1.81 mmol/l) affected 50% of maximum response change (−1.74%) for HbA1c from the response of placebo (−0.253%).

We considered inclusion of this moiety to be important for our inhibitors and proposed the achiral 2-amino thiazole-5-carboxylate scaffold as an alternative to the TLM substructure to combine pharmacodynamic potency with essential pharmacokinetic considerations such as solubility.

Gemifloxacin was approved after Scheld's review and has pharmacodynamic potency similar to moxifloxacin against S. pneumoniae.

Ciprofloxacin has pharmacodynamic potency against P. aeruginosa, a track record of safety in large populations, and a large published literature.

The main pharmacodynamic parameters (potency, efficacy, and sensitivity) were estimated for four endpoints (body temperature, creeping speed, ground vertical reaction force and clinical lameness score).

A key feature of this work is the combination of balanced potency and pharmacodynamic duration with desirable pharmacokinetic and material properties, whilst keeping synthetic complexity to a minimum.

These biopharmaceutical/pharmacokinetic variables should also be related to pharmacodynamic and toxicological variables such potency and duration of effect.

The PEGylated proteins were evaluated for reaction specificity by SDS‐PAGE and peptide mapping, in vitro potency, pharmacokinetic and pharmacodynamic properties, and efficacy in a sciatic nerve injury model.

EC154 is a compound with improved properties (potency, pharmacokinetic and pharmacodynamic) over BIIB021, the first oral synthetic Hsp90 inhibitor to reach clinical trials [ 51].

The higher risk of pneumonia in patients treated with fluticasone/salmeterol might be related to differences in immunosuppressant potency and pharmacokinetic and pharmacodynamic properties between budesonide and fluticasone.